SCHEMBL987203

SCHEMBL987203

Nc1cnc2[nH]c(-c3cccnc3)nc2c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.60
HTT P42858 1/20 0.60
HPGD P15428 3/20 0.54
ALDH1A1 P00352 3/20 0.54
KDM4E B2RXH2 2/20 0.54
RAB9A P51151 2/20 0.54
NPC1 O15118 1/20 0.54
STAT1 P42224 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
LDHA P00338 1/20 0.52
EPHX2 P34913 1/20 0.52
CYP11B1 P15538 1/20 0.50
LMNA P02545 1/20 0.48
POLB P06746 1/20 0.48
KDM4C Q9H3R0 1/20 0.48
TP53 P04637 1/20 0.47
GFER P55789 1/20 0.47
KMT2A Q03164 1/20 0.46
HSD17B10 Q99714 1/20 0.45
PNP P00491 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL986878 0.85 ALDH1A1 (0.54) MAPTHTTHPGDALDH1A1KDM4E
SCHEMBL983953 0.84 ALDH1A1 (0.45) MAPTHTTHPGDALDH1A1KDM4E
SCHEMBL15427088 0.83 MAPT (0.57) MAPTHTTHPGDALDH1A1KDM4E
SCHEMBL29526609 0.82 KDM4E (0.66) MAPTHTTHPGDALDH1A1KDM4E
SCHEMBL3027718 0.81 KDM4E (0.56) MAPTHTTHPGDALDH1A1KDM4E
SCHEMBL5621043 0.80 ALDH1A1 (0.54) MAPTHTTHPGDALDH1A1KDM4E
SCHEMBL984463 0.79 HRH1 (0.48) MAPTHPGDALDH1A1KDM4ERAB9A
SCHEMBL986735 0.79 HRH1 (0.48) MAPTHPGDALDH1A1KDM4ERAB9A
SCHEMBL3541175 0.78 MAPT (0.79) MAPTHTTHPGDALDH1A1KDM4E
SCHEMBL986022 0.78 RAB9A (0.65) MAPTHTTHPGDALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2265609-B1 IMDIZO [4. 5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS ARRAY BIOPHARMA INC (US) 2012-09-05 EP disclosed
US-20110003809-A1 IMIDAZO [4,5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS ARRAY BIOPHARMA INC. 2011-01-06 US disclosed
EP-2265609-A1 IMDIZO [4. 5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS Array Biopharma, Inc. (US) 2010-12-29 EP disclosed
WO-2009111277-A9 IMIDAZO [4. 5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS ARRAY BIOPHARMA INC. (US) 2009-12-30 WO disclosed
WO-2009111277-A1 IMDIZO [4. 5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS ARRAY BIOPHARMA INC. (US) 2009-09-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003809-A1 IMIDAZO [4,5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS BRAF, RAF1, ARAF MAPT 4751/4885HTT 4873/4885HPGD 1413/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.